Rikke Hald Selected Research

futuximab

1/2020	Population pharmacokinetics and covariate analysis of Sym004, an antibody mixture against the epidermal growth factor receptor, in subjects with metastatic colorectal cancer and other solid tumors.
6/2015	Safety and Activity of the First-in-Class Sym004 Anti-EGFR Antibody Mixture in Patients with Refractory Colorectal Cancer.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Rikke Hald Research Topics

Disease

3	Neoplasms (Cancer) 01/2020 - 06/2015
2	Colorectal Neoplasms (Colorectal Cancer) 01/2020 - 06/2015
1	Body Weight (Weight, Body) 01/2020

Drug/Important Bio-Agent (IBA)

2	futuximabIBA 01/2020 - 06/2015
1	ErbB Receptors (EGF Receptor)IBA 01/2020
1	AlbuminsIBA 01/2020
1	Immunoglobulin G (IgG)IBA 10/2017
1	emibetuzumabIBA 10/2017
1	Receptor Protein-Tyrosine Kinases (Tyrosine Kinase Receptors)IBA 10/2017
1	Panitumumab (Vectibix)FDA Link 06/2015
1	Cetuximab (Erbitux)FDA Link 06/2015
1	LigandsIBA 06/2015